NRXP Share Price Performance
US$2.36
1.15 (95.04%)
Price US$2.36
Share Pricen/a
NRx Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 22 Fair Values set on narratives written by author
NRXP Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
NRx Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.35
- 59.92%
- -15,727.27%
- -38.5%
About NRXP
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
